[Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection].
OBJECTIVE
To provide an update of the metabolic and morphologic alterations in patients infected with HIV with an in-depth analysis of their clinical management and treatment.


METHODS
These recommendations were agreed by consensus by a committee of experts in metabolic alterations and HIV patient care, under the auspices of the Secretariat for the National AIDS Plan. To do this, the latest clinical, epidemiological and physiopathological advances described in studies published in the scientific literature and/or presented in congresses were reviewed.


RESULTS
The most frequent metabolic alterations in HIV patients and in antiretroviral treatment (ART) are dyslipidemia with an atherogenic profile and alterations in carbohydrate metabolism/insulin resistance. A high prevalence of cardiovascular risk factors, especially smoking, has been described. The same criteria for their management as those used in the general population have been employed, with specific nuances. Diet and exercise should be the first therapeutic recommendation. In patients with dyslipidemia who require drug treatment, statins and/or fibrates are indicated. Glitazones have demonstrated efficacy in the treatment of insulin resistance. The approach to anomalous fat distribution continues to be controversial. The main approaches at present are a switch of ART, reparative surgery, psychological support and lifestyle changes. Lactic acidosis is an infrequent but highly serious complication, and the first step is withdrawal of ART. In bone metabolism alterations, prevention and early detection are essential, especially in children and perimenopausal women. Sexual dysfunction is a frequent problem in both men and women; because the causes are highly varied, treatment should be individualized.


CONCLUSIONS
The prevalence of metabolic and morphologic alterations has increased since the introduction of highly active antiretroviral treatment (HAART). Knowledge of the various aspects involved in their diagnosis and treatment is essential for the appropriate care of patients with HIV infection.
Polo
Rosa
R
Consejera Técnica, Plan Nacional sobre el Sida, Madrid, España. rpolor@msc.es
José Galindo
M
M
Martínez
Esteban
E
Alvarez
Julia
J
Arévalo
José Manuel
JM
Asensi
Víctor
V
Cánoves
Dolores
D
Cáncer
Emilia
E
Collazos
Julio
J
Estrada
Vicente
V
Gómez-Candela
Carmen
C
Johnston
Susan
S
Locutura
Jaime
J
López-Aldeguer
José
J
Lozano
Fernando
F
Miralles
Celia
C
Muñoz-Sanz
Agustín
A
Ortega
Enrique
E
Pascua
Javier
J
Pedrol
Enric
E
Pulido
Federico
F
San Martín
Miguel
M
Sanz
Jesús
J
Viciana
Pompeyo
P
Chamorro
Lourdes
L
D000140:Acidosis, Lactic / Q000209:etiology / Q000517:prevention & control; D000465:Algorithms; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000209:etiology / Q000517:prevention & control; D050171:Dyslipidemias / Q000209:etiology / Q000517:prevention & control; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000517:prevention & control* / Q000601:surgery; D006801:Humans; D007333:Insulin Resistance; D050356:Lipid Metabolism; D012307:Risk Factors; D012735:Sexual Dysfunction, Physiological / Q000209:etiology / Q000517:prevention & control; D013315:Stress, Psychological / Q000209:etiology / Q000517:prevention & control